Samsung Bioepis Enters into a Strategic Partnership with NIPRO for Commercialization of Multiple Biosimilars in Japan

#Samsung #SamsungBioepisNIPROPartnership #SamsungBioepis #Biosimilars

Source: Samsung Bioepis

June 2025 : Samsung Bioepis and NIPRO Corporation have partnered for the license, development, and commercialization of several biosimilar candidates in Japan. This agreement includes SB17, Samsung Bioepis' ustekinumab biosimilar candidate.

Under the terms of the agreement, Samsung Bioepis will be responsible for the development, manufacture and supply of the medicines, while NIPRO will be responsible for commercialization of the medicines in Japan.

“This partnership marks an important step towards expanding our footprint in Japan. Biosimilars have a great potential to bring cost savings and widen access to treatments for healthcare systems, providers, and patients in Japan. We look forward to collaborating with NIPRO, a company renowned for its high-quality medical devices and healthcare solutions, to accelerate access to treatments in the Japanese market,” said Kyung-Ah Kim, President and Chief Executive Officer, Samsung Bioepis. “We will continue to advance our development platform and innovate access to treatments for healthcare systems, payers, physicians, and patients around the world.”